Related Experiment Video
Updated: Jun 12, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Molecularly targeted agents for renal cell carcinoma: the next generation
C Lance Cowey1, Thomas E Hutson
1Genitourinary Oncology and Melanoma Program, Baylor University Medical Center, Sammons Cancer Center, Dallas, TX 75246, USA. lance.cowey@usoncology.com
Abstract:
With the approval of several molecularly targeted agents over the past few years, the landscape of renal cell carcinoma (RCC) management has drastically changed. Response rates and survival have improved with these new agents compared to the previous standard of cytokine-based therapy. Many new agents are in various stages of development, and how these novel therapies will be incorporated into the paradigm of RCC treatment is yet to be determined. The development of optimal sequencing and combinations of these drugs is important to improving patient outcomes and overcoming resistance mechanisms.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Site-Targeted
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Cancer

